Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.

IMM Insider Trading (ImmuPharma)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £10,000
Insider Selling (Last 12 Months): GBX 0

ImmuPharma Insider Trading History Chart

This chart shows the insider buying and selling history at ImmuPharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ImmuPharma Share Price & Price History

Current Price: GBX 5.17
Price Change: +0.30 (1.20%)
As of 08/12/2022 01:00 AM ET

This chart shows the closing price history over time for IMM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!

ImmuPharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2021Sanjeev PandyaInsiderBuy125,000GBX 8£10,000
See Full Table
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.

SEC Filings (Institutional Ownership Changes) for ImmuPharma (LON:IMM)

ImmuPharma logo
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Read More on ImmuPharma

Today's Range

Now: GBX 5.17
Low: 5.04
High: 5.48

50 Day Range

MA: GBX 5.78
Low: 5.14
High: 6.67

52 Week Range

Now: GBX 5.17
Low: 4.80
High: 9.50

Volume

1,532,677 shs

Average Volume

1,137,458 shs

Market Capitalization

£14.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of ImmuPharma?

ImmuPharma's top insider shareholders include:
  1. Sanjeev Pandya (Insider)
Learn More about top insider investors at ImmuPharma.
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.